TW200400035A - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
TW200400035A
TW200400035A TW092106766A TW92106766A TW200400035A TW 200400035 A TW200400035 A TW 200400035A TW 092106766 A TW092106766 A TW 092106766A TW 92106766 A TW92106766 A TW 92106766A TW 200400035 A TW200400035 A TW 200400035A
Authority
TW
Taiwan
Prior art keywords
methyl
formula
compound
urea
morpholin
Prior art date
Application number
TW092106766A
Other languages
English (en)
Chinese (zh)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Alistair Hayes Martin
Teanby Hodgson Simon
Bruce Judd Duncan
Elaine Keeling Suzanne
Qing Lewell Xiao
Mills Gail
Michael Robertson Graeme
Swanson Stephen
John Walker Andrew
Wilkinson Mark
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200400035A publication Critical patent/TW200400035A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW092106766A 2002-03-28 2003-03-26 Novel compounds TW200400035A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds

Publications (1)

Publication Number Publication Date
TW200400035A true TW200400035A (en) 2004-01-01

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092106766A TW200400035A (en) 2002-03-28 2003-03-26 Novel compounds

Country Status (23)

Country Link
US (1) US7622464B2 (https=)
EP (1) EP1487828B1 (https=)
JP (1) JP4465195B2 (https=)
KR (1) KR20040093488A (https=)
CN (1) CN1656092A (https=)
AR (1) AR040403A1 (https=)
AT (1) ATE413399T1 (https=)
AU (1) AU2003226757A1 (https=)
BR (1) BR0308780A (https=)
CA (1) CA2480106A1 (https=)
CY (1) CY1108652T1 (https=)
DE (1) DE60324535D1 (https=)
DK (1) DK1487828T3 (https=)
ES (1) ES2315519T3 (https=)
IL (1) IL164047A0 (https=)
IS (1) IS7444A (https=)
MX (1) MXPA04009459A (https=)
NO (1) NO20044448L (https=)
PT (1) PT1487828E (https=)
RU (1) RU2004127928A (https=)
SI (1) SI1487828T1 (https=)
TW (1) TW200400035A (https=)
WO (1) WO2003082861A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
WO2022023496A2 (en) * 2020-07-29 2022-02-03 Universidade De Santiago De Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
WO1995032196A1 (en) 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
NZ290788A (en) 1994-07-20 1999-07-29 Byk Gulden Lomberg Chem Fab Piperazine thiopyridines; used for controlling helicobacter bacteria
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
ATE413399T1 (de) 2008-11-15
IS7444A (is) 2004-09-13
IL164047A0 (en) 2005-12-18
NO20044448L (no) 2004-10-26
AU2003226757A1 (en) 2003-10-13
ES2315519T3 (es) 2009-04-01
US20060063765A1 (en) 2006-03-23
CY1108652T1 (el) 2014-08-13
SI1487828T1 (sl) 2009-04-30
CA2480106A1 (en) 2003-10-09
WO2003082861A3 (en) 2004-03-11
JP4465195B2 (ja) 2010-05-19
US7622464B2 (en) 2009-11-24
RU2004127928A (ru) 2005-06-27
EP1487828B1 (en) 2008-11-05
DK1487828T3 (da) 2009-02-02
PT1487828E (pt) 2009-01-06
DE60324535D1 (de) 2008-12-18
KR20040093488A (ko) 2004-11-05
EP1487828A2 (en) 2004-12-22
CN1656092A (zh) 2005-08-17
JP2005526815A (ja) 2005-09-08
WO2003082861A2 (en) 2003-10-09
MXPA04009459A (es) 2005-01-25
AR040403A1 (es) 2005-04-06
BR0308780A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
TW200400035A (en) Novel compounds
AU2020273302B2 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
EP2592933B1 (en) Mif inhibitors and their uses
JP6349360B2 (ja) Cb2アゴニストとして有用なピリジン−2−アミド
US8981084B2 (en) Oxadiazole HDAC inhibitors
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
US20110183974A1 (en) 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists
KR101589775B1 (ko) 트리아졸 유도체 또는 그의 염
JP2019142874A (ja) ピペリジンcxcr7受容体調節剤
TW201002685A (en) Heterocyclic compound and use thereof
ZA200606941B (en) Compounds and methods of use
MX2012005518A (es) Derivados de pirazol amina triciclica.
JP2012515788A (ja) 自己免疫疾患および炎症性疾患の処置における、s1pアゴニストとしての置換オキサジアゾール誘導体
JPWO2019107386A1 (ja) 抗腫瘍剤
KR20140117651A (ko) 이소퀴놀린 및 나프티리딘 유도체
TW200402419A (en) Novel compounds
TW200403063A (en) Novel compounds